Isis Pharmaceuticals has secured a collaboration deal with GlaxoSmithKline which will see the latter pay $35 million in upfront cash and additional milestones in return for an option to license up to six anti-RNA therapeutic compounds at Phase II proof of concept. The deal covers rare and infectious diseases, and the targets will be contributed by GSK.
Isis Pharmaceuticals has secured a collaboration deal with GlaxoSmithKline which will see the latter pay $35 million in upfront cash and additional milestones in return for an option to license up to six anti-RNA therapeutic compounds at Phase II proof of concept. The deal covers rare and infectious diseases, and the targets will be contributed by GSK.
The Californian antisense therapy company will be eligible for around $20 million in milestones per programme up to Phase II...
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
